Competing risk regression models for epidemiologic data.

Competing events can preclude the event of interest from occurring in epidemiologic data and can be analyzed by using extensions of survival analysis methods. In this paper, the authors outline 3 regression approaches for estimating 2 key quantities in competing risks analysis: the cause-specific relative hazard ((cs)RH) and the subdistribution relative hazard ((sd)RH). They compare and contrast the structure of the risk sets and the interpretation of parameters obtained with these methods. They also demonstrate the use of these methods with data from the Women's Interagency HIV Study established in 1993, treating time to initiation of highly active antiretroviral therapy or to clinical disease progression as competing events. In our example, women with an injection drug use history were less likely than those without a history of injection drug use to initiate therapy prior to progression to acquired immunodeficiency syndrome or death by both measures of association ((cs)RH = 0.67, 95% confidence interval: 0.57, 0.80 and (sd)RH = 0.60, 95% confidence interval: 0.50, 0.71). Moreover, the relative hazards for disease progression prior to treatment were elevated ((cs)RH = 1.71, 95% confidence interval: 1.37, 2.13 and (sd)RH = 2.01, 95% confidence interval: 1.62, 2.51). Methods for competing risks should be used by epidemiologists, with the choice of method guided by the scientific question.

[1]  J. Cornfield,et al.  The estimation of the probability of developing a disease in the presence of competing risks. , 1957, American journal of public health and the nation's health.

[2]  D. Cox,et al.  THE ANALYSIS OF EXPONENTIALLY DISTRIBUTED LIFE-TIMES WITH Two TYPES OF FAILURE , 1959 .

[3]  H. Seal Studies in the history of probability and statistics , 1977 .

[4]  C. L. Chiang,et al.  Competing Risks and Conditional Probabilities , 1970 .

[5]  V T Farewell,et al.  The analysis of failure times in the presence of competing risks. , 1978, Biometrics.

[6]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[7]  Gregg E. Dinse,et al.  A mixture model for the regression analysis of competing risks data , 1985 .

[8]  B. Efron The jackknife, the bootstrap, and other resampling plans , 1987 .

[9]  R. Gray A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .

[10]  E L Korn,et al.  Applications of crude incidence curves. , 1992, Statistics in medicine.

[11]  M S Pepe,et al.  Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data? , 1993, Statistics in medicine.

[12]  Jeffrey J. Gaynor,et al.  On the Use of Cause-Specific Failure and Conditional Failure Probabilities: Examples from Clinical Oncology Data , 1993 .

[13]  J. Klein,et al.  Statistical Models Based On Counting Process , 1994 .

[14]  M Lunn,et al.  Applying Cox regression to competing risks. , 1995, Biometrics.

[15]  D. Lin,et al.  Non-parametric inference for cumulative incidence functions in competing risks studies. , 1997, Statistics in medicine.

[16]  Joseph Feldman,et al.  The Women's Interagency HIV Study , 1998 .

[17]  D. Cotton Do we still need a cohort study of women with HIV infection? , 1998, Epidemiology.

[18]  M. Kenward,et al.  Contribution to the discussion of the paper by Diggle, Tawn and Moyeed , 1998 .

[19]  L. Kalish,et al.  The Women's Interagency HIV Study. WIHS Collaborative Study Group. , 1998, Epidemiology.

[20]  V. M. Shadle,et al.  Self-reported antiretroviral therapy in injection drug users. , 1998, JAMA.

[21]  Lee-Jen Wei,et al.  Prediction of cumulative incidence function under the proportional hazards model. , 1998, Biometrics.

[22]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[23]  James M. Robins,et al.  Causal Inference Without Counterfactuals: Comment , 2000 .

[24]  Richard D Moore,et al.  Detrimental Effects of Continued Illicit Drug Use on the Treatment of HIV‐1 Infection , 2001, Journal of acquired immune deficiency syndromes.

[25]  D. Vlahov,et al.  Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users , 2001, AIDS.

[26]  M. Crowder Classical Competing Risks , 2001 .

[27]  Susanne Rosthøj,et al.  Competing risks as a multi-state model , 2002, Statistical methods in medical research.

[28]  Anne M Johnson,et al.  Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. , 2002, International journal of epidemiology.

[29]  Laurence L. George,et al.  The Statistical Analysis of Failure Time Data , 2003, Technometrics.

[30]  M. Zwahlen,et al.  All cause mortality in the Swiss HIV cohort study from 1990 to 2001 in comparison with the Swiss population , 2004, AIDS.

[31]  J. Satagopan,et al.  A note on competing risks in survival data analysis , 2004, British Journal of Cancer.

[32]  M. Young,et al.  The Women's Interagency HIV Study: an Observational Cohort Brings Clinical Sciences to the Bench , 2005, Clinical Diagnostic Laboratory Immunology.

[33]  G. Leung,et al.  Methods for Estimating the Case Fatality Ratio for a Novel, Emerging Infectious Disease , 2005, American journal of epidemiology.

[34]  Melania Pintilie,et al.  Competing Risks: A Practical Perspective , 2006 .

[35]  J. Castilla,et al.  Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain. , 2006, AIDS research and human retroviruses.

[36]  Haitao Chu,et al.  Parametric survival analysis and taxonomy of hazard functions for the generalized gamma distribution , 2007, Statistics in medicine.

[37]  Richard D Moore,et al.  Risk of Non-AIDS-Related Mortality May Exceed Risk of AIDS-Related Mortality Among Individuals Enrolling Into Care With CD4+ Counts Greater Than 200 Cells/mm3 , 2007, Journal of acquired immune deficiency syndromes.

[38]  M. Wolbers,et al.  Comments on ‘Analysing and interpreting competing risk data’ (original article and author's reply) by Melania Pintilie, Statistics in Medicine 2007; 26:1360–1367; DOI: 10.1002/sim.2655 (original article) and Statistics in Medicine 2007; DOI: 10.1002/sim.2822 (author's reply) , 2007, Statistics in medicine.

[39]  Martin Schumacher,et al.  Misspecified regression model for the subdistribution hazard of a competing risk by Latouche A, Boisson V, Chevret S and Porcher R. Statistics in Medicine 2006; DOI: 10.2002/sim.2600 , 2007, Statistics in medicine.

[40]  Mardge H. Cohen,et al.  Mortality among participants in the Multicenter AIDS Cohort Study and the Women's Interagency HIV Study. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[41]  Melania Pintilie,et al.  Analysing and interpreting competing risk data , 2007, Statistics in medicine.

[42]  J Beyersmann,et al.  Comments on ‘Analysing and interpreting competing risk data’ by M. Pintilie, Statistics in Medicine 2006. DOI: 10.1002/sim.2655 , 2007, Statistics in medicine.

[43]  A. D'Amico,et al.  Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. , 2007, Journal of the National Cancer Institute.

[44]  Martin Schumacher,et al.  A competing risks analysis of bloodstream infection after stem‐cell transplantation using subdistribution hazards and cause‐specific hazards , 2007, Statistics in medicine.

[45]  Bryan Lau,et al.  Evaluating competing adverse and beneficial outcomes using a mixture model , 2008, Statistics in medicine.

[46]  Mardge H. Cohen,et al.  Patterns, predictors, and consequences of initial regimen type among HIV-infected women receiving highly active antiretroviral therapy. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[47]  O. Kirk,et al.  Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration , 2008, The Lancet.

[48]  J. Hanley The Breslow estimator of the nonparametric baseline survivor function in Cox's regression model: some heuristics. , 2008, Epidemiology.

[49]  Qian-Li Xue,et al.  Life-space constriction, development of frailty, and the competing risk of mortality: the Women's Health And Aging Study I. , 2007, American journal of epidemiology.